IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-0.49%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$312M
AUM Growth
+$312M
(+3,153%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
89.54%
Top 10 Holdings %
Top 10 Hldgs %
48.33%
Holding
84
New
6
Increased
59
Reduced
1
Closed
18
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$26.7M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$21.2M |
| 3 |
Incyte
INCY
|
$18M |
| 4 |
Alkermes
ALKS
|
$13.2M |
| 5 |
Gilead Sciences
GILD
|
$12.3M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$1.94M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$121K |
| 3 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
$107K |
| 4 |
Amicus Therapeutics
FOLD
|
$94.6K |
| 5 |
Immunovant
IMVT
|
$60K |
Sector Composition
| 1 | Healthcare | 99.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Guardant Health
GH
$8.11B
| $4M | 1.28% |
74,500
+71,495
| +2,379% | +$3.84M |
|
27
Amgen
AMGN
$153B
| $3.66M | 1.17% |
16,246
+6,331
| +64% | +$1.43M |
|
|
RVNC
28
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.24M | 1.04% |
+120,000
| New | +$3.24M |
|
29
Neurocrine Biosciences
NBIX
$13.5B
| $3.19M | 1.02% |
30,000
+6,992
| +30% | +$742K |
|
30
United Therapeutics
UTHR
$17.7B
| $3.14M | 1.01% |
15,000
+10,287
| +218% | +$2.15M |
|
31
Krystal Biotech
KRYS
$4.35B
| $3.13M | 1% |
45,000
+42,045
| +1,423% | +$2.93M |
|
32
Viatris
VTRS
$12.3B
| $3.1M | 0.99% |
+364,000
| New | +$3.1M |
|
33
Ascendis Pharma
ASND
$12.1B
| $3.04M | 0.97% |
29,400
+26,667
| +976% | +$2.75M |
|
34
Caribou Biosciences
CRBU
$176M
| $2.72M | 0.87% |
257,892
+256,514
| +18,615% | +$2.7M |
|
35
Fate Therapeutics
FATE
$115M
| $2.71M | 0.87% |
121,000
+117,083
| +2,989% | +$2.62M |
|
36
Zai Lab
ZLAB
$3.48B
| $2.69M | 0.86% |
78,958
+76,222
| +2,786% | +$2.6M |
|
37
NovoCure
NVCR
$1.35B
| $2.43M | 0.78% |
32,000
+29,776
| +1,339% | +$2.26M |
|
38
Novavax
NVAX
$1.2B
| $2.41M | 0.77% |
132,500
+125,686
| +1,845% | +$2.29M |
|
39
Jazz Pharmaceuticals
JAZZ
$7.99B
| $2.29M | 0.73% |
17,200
+14,517
| +541% | +$1.93M |
|
40
CRISPR Therapeutics
CRSP
$4.82B
| $2.24M | 0.72% |
34,200
+32,122
| +1,546% | +$2.1M |
|
41
Adicet Bio
ACET
$60.8M
| $2.2M | 0.7% |
+154,708
| New | +$2.2M |
|
|
ONC
42
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $2.12M | 0.68% |
15,700
+13,158
| +518% | +$1.77M |
|
|
IMAB
43
I-MAB
IMAB
$380M
| $2.02M | 0.65% |
507,239
+501,007
| +8,039% | +$2M |
|
44
IDEAYA Biosciences
IDYA
$2.26B
| $1.63M | 0.52% |
109,000
+107,499
| +7,162% | +$1.6M |
|
45
Fulcrum Therapeutics
FULC
$353M
| $1.56M | 0.5% |
193,741
+192,792
| +20,315% | +$1.56M |
|
46
Legend Biotech
LEGN
$6.64B
| $1.55M | 0.5% |
38,000
+37,752
| +15,223% | +$1.54M |
|
|
CNCE
47
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $1.35M | 0.43% |
200,800
+198,190
| +7,593% | +$1.33M |
|
48
Intellia Therapeutics
NTLA
$1.26B
| $1.34M | 0.43% |
24,000
+22,758
| +1,832% | +$1.27M |
|
49
Denali Therapeutics
DNLI
$2.24B
| $1.17M | 0.37% |
38,000
+36,882
| +3,299% | +$1.13M |
|
50
Beam Therapeutics
BEAM
$1.9B
| $1.12M | 0.36% |
23,500
+22,590
| +2,482% | +$1.08M |
|